Intercept price target raised to $525 from $360 at Oppenheimer Oppenheimer increased its price target on Intercept after updating its valuation estimate of the company's OCA drug after positive data for the drug was reported. The firm thinks the stock could rise further as investors focus on potentially positive upcoming fibrosis data. Oppenheimer keeps an Outperform rating on the shares.
Intercept price target lowered to $475 from $693 at Citigroup Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCA’s cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.